NDC product
Ephedrine Sulfate
NDC 68083-495 · Gland Pharma Limited
Key facts
| Product NDC | 68083-495 |
|---|---|
| Proprietary name | Ephedrine Sulfate |
| Nonproprietary name | Ephedrine Sulfate |
| Substances | EPHEDRINE SULFATE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | Gland Pharma Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA216146 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Increased Norepinephrine Activity [PE], Norepinephrine Releasing Agent [EPC], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC] |
| Marketing start | Feb 25, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: